Canasa Pac Side Effects

Generic Name: mesalamine

Note: This page contains information about the side effects of mesalamine. Some of the dosage forms included on this document may not apply to the brand name Canasa Pac.

Not all side effects for Canasa Pac may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to mesalamine: oral capsule delayed release, oral capsule extended release, oral tablet, oral tablet delayed release, oral tablet enteric coated

In addition to its needed effects, some unwanted effects may be caused by mesalamine (the active ingredient contained in Canasa Pac). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking mesalamine:

More common
  • Abdominal or stomach pain (severe)
  • bloody diarrhea
  • rectal bleeding
Less common
  • Abdominal or stomach cramps (severe)
  • blurred vision
  • dizziness
  • fever
  • full or bloated feeling
  • headache (severe)
  • nervousness
  • pounding in the ears
  • pressure in the stomach
  • skin rash and itching
  • slow or fast heartbeat
  • swelling of the abdominal or stomach area
  • unusual tiredness or weakness
  • Anxiety
  • back pain (severe)
  • blue or pale skin
  • chest pain, possibly moving to the left arm, neck, or shoulder
  • chills
  • nausea or vomiting
  • shortness of breath
  • yellow eyes or skin

Some of the side effects that can occur with mesalamine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Abdominal or stomach cramps or pain (mild)
  • diarrhea (mild)
  • headache (mild)
  • runny or stuffy nose
  • sneezing
Less common
  • Acid or sour stomach
  • acne
  • back or joint pain
  • belching
  • difficulty with moving
  • excess air or gas in the stomach or intestines
  • hair loss or thinning of the hair
  • heartburn
  • indigestion
  • loss of appetite
  • muscle pain or stiffness
  • passing gas
  • stomach discomfort or upset

For Healthcare Professionals

Applies to mesalamine: compounding powder, oral capsule extended release, oral delayed release capsule, oral delayed release tablet, rectal enema, rectal kit, rectal suppository


Colitis symptoms (including cramping, acute abdominal pain, and bloody diarrhea, and occasionally fever, headache, malaise, pruritus, rash, and conjunctivitis) have been exacerbated after starting mesalamine (the active ingredient contained in Canasa Pac) or sulfasalazine in 3% of patients in controlled clinical trials. This acute intolerance syndrome may be difficult to distinguish from a flare of inflammatory bowel disease.

Worsening of colitis or symptoms of inflammatory bowel disease, including melena and hematochezia, have also been reported after commencing mesalamine rectal suspension enema.[Ref]

Very common (10% or more): Abdominal pain (up to 18%), eructation (up to 16%), nausea (up to 13%)
Common (1% to 10%): Diarrhea (up to 8%), dyspepsia (up to 6%), ulcerative colitis (up to 5.8%), vomiting (up to 5%), constipation (up to 5%), upper abdominal pain (up to 5%), gastrointestinal bleeding (up to 5% or greater), flatulence (up to 5% or greater), acute intolerance syndrome (3%), colitis exacerbation (up to 3%), lower abdominal pain (less than 3%), rectal hemorrhage (less than 3%), gastroenteritis (2% or greater), gastrointestinal hemorrhage (2% or greater), stool abnormalities (color or texture change; up to 2% or greater), tenesmus (up to 2% or greater), rectal disorder (2% or greater), abdominal enlargement (up to 2% or greater), abdominal distention (up to 1.3%)
Rare (less than 0.1%): Colitis, pancreatitis, rectal polyp, duodenal ulcer, esophageal ulcer, dysphagia, fecal incontinence, oral moniliasis, thirst, recurrence of ulcerative colitis, gastritis, stomatitis, perforated peptic ulcer
Frequency not reported: Worsening of colitis or symptoms of inflammatory bowel disease (including melena and hematochezia), elevated amylase, elevated lipase
Postmarketing reports: Pancreatitis, gastritis, dry mouth, oral ulcers, gastroenteritis, gastrointestinal bleeding, perforated peptic ulcer, bloody diarrhea, taste perversion[Ref]

Nervous system

Very common (10% or more): Headache (up to 35%)
Common (1% to 10%): Dizziness (up to 8%), lightheadedness (8%), faintness (8%), tinnitus (less than 3%), vertigo (less than 3%), migraine (2% or greater), paresthesia (up to 2% or greater), insomnia (up to 2%)
Rare (less than 0.1%): Benign intracranial hypertension (at least 1 case)
Postmarketing reports: Systemic lupus erythematosus, peripheral neuropathy, Guillain-Barre syndrome, transverse myelitis, somnolence, tremor, hyperesthesia, tinnitus, vertigo[Ref]

A 23-year-old female with ulcerative colitis who had been taking 400 mg mesalamine tablets three times a day developed benign intracranial hypertension. The examination disclosed benign intracranial hypertension that resolved when mesalamine was discontinued and recurred when the drug was restarted.[Ref]


Very common (10% or more): Muscle aches (21%)
Common (1% to 10%): Back pain (up to 7%), arthralgia (up to 5% or greater), hypertonia (5%), myalgia (up to 3%), joint disorder (2% or greater), arthritis (2%)
Frequency not reported: Leg cramps, rheumatoid arthritis
Postmarketing reports: Gout, myalgia[Ref]


A 72-year-old female with ulcerative colitis who had begun taking two 400 mg mesalamine (the active ingredient contained in Canasa Pac) tablets twice daily experienced pleural effusion and pulmonary infiltrates. Chest radiograph showed bilateral pleural effusions and an infiltrate in the lower lobe of the right lung. It was determined that the adverse events described appeared likely to be due to mesalamine therapy.

Pleural effusion and pulmonary infiltrates, generally accompanied by eosinophilia, have been reported rarely. More severe cases have included fibrosing alveolitis.[Ref]

Very common (10% or more): Nasopharyngitis (up to 11%)
Common (1% to 10%): Rhinitis (up to 9%), influenza and influenza-like illness (up to 5% or greater), sinusitis (3%), dyspnea (less than 3%), bronchitis (2% or greater), increased cough (2%)
Rare (less than 0.1%): Pleural effusion, pulmonary infiltrates, fibrosing alveolitis
Postmarketing reports: Eosinophilic pneumonia, interstitial pneumonitis, asthma exacerbation, pleuritis, pneumonitis, hypersensitivity pneumonitis, allergic alveolitis[Ref]


Common (1% to 10%): Chest pain of unknown etiology (3%), vasodilation (up to 2% or greater)
Uncommon (0.1% to 1%): Hypertension (up to 1%)
Rare (less than 0.1%): Tachycardia, hypotension, palpitations, pericarditis, pericardial effusion, myocarditis, T-wave abnormalities, severe symptomatic sinus bradycardia (at least 1 case), pleuropericarditis (at least 1 case)
Postmarketing reports: Angioedema, myocarditis, pericardial effusion, pericarditis[Ref]

One 20-year-old patient died of cardiac arrhythmias attributed to myocarditis 13 days after starting mesalamine.

A 56-year-old male with hypertension and ulcerative proctitis experienced pleuropericarditis coincident with mesalamine therapy. Evaluation revealed acute pleuropericarditis manifested by ECG changes, pericardial effusion, and a small pleural effusion. All symptoms resolved when mesalamine was discontinued.[Ref]


Very common (10% or more): Pain (in various parts of the body; up to 14%)
Common (1% to 10%): Asthenia (up to 7%), fever (up to 6%), chills (3%), peripheral edema (3%), fatigue (up to 3%), ear disorder (2% or greater), infection (2% or greater), malaise (2%)
Frequency not reported: Pyrexia, pharyngolaryngeal pain, ear pain, ear congestion
Postmarketing reports: Lupus-like syndrome, drug fever, neck pain, facial edema, edema[Ref]


Common (1% to 10%): Rash (up to 7%), sweating (up to 3%), pruritus (up to 3%), alopecia (less than 3%), acne (up to 2%)
Rare (less than 0.1%): Lupus erythematosus-like reactions, prurigo, eczema, lichen planus, nail disorder, photosensitivity, folliculitis
Postmarketing reports: Psoriasis, alopecia, pyoderma gangrenosum, dry skin, erythema nodosum, urticaria, Stevens-Johnson syndrome[Ref]


Common (1% to 10%): Decreased hematocrit and hemoglobin (less than 3%)
Rare (less than 0.1%): Agranulocytosis, aplastic anemia
Frequency not reported: Neutropenia, pancytopenia, ecchymosis, thrombocythemia, decreased platelet count
Postmarketing reports: Granulocytopenia, agranulocytosis, aplastic anemia, thrombocytopenia, eosinophilia, leukopenia, anemia, lymphadenopathy[Ref]


Common (1% to 10%): Rash and pruritus (greater than 2%); arthralgias, myalgias, and fever (greater than 1%)
Uncommon (0.1% to 1%): Allergic reactions (which could involve eosinophilia), hepatitis, interstitial pneumonitis, pericarditis
Rare (less than 0.1%): Hypersensitivity reactions (such as hypersensitivity pneumonitis, angioedema, erythroderma, toxic epidermal necrolysis, palmar-plantar erythrodysesthesia, hypereosinophilia), pruriginous rash (at least 2 cases)
Frequency not reported: Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis)
Postmarketing reports: Anaphylactic reaction, drug reaction with eosinophilia and systemic symptoms (DRESS)[Ref]

A male patient with ulcerative colitis experienced pruriginous rash coincident with mesalamine therapy. He experienced the cutaneous hypersensitivity reaction 48 hours after initiating therapy with mesalamine 500 mg orally every 8 hours. After mesalamine was suspended and antihistamines were given, the patient recovered. Upon reintroduction of mesalamine, the symptoms appeared again 24 hours later.[Ref]


Common (1% to 10%): Cholestatic hepatitis (less than 3%), elevated transaminases (less than 3%), abnormal liver function test (up to 2.3%)
Rare (less than 0.1%): Granulomatous hepatitis (at least 1 case)
Frequency not reported: Hepatitis (presenting with rash, fever, abdominal pain, nausea, vomiting, chills, dizziness, hepatomegaly, lymphadenopathy, and laboratory abnormalities [including elevated liver function tests, eosinophilia, and leukocytosis]), hepatic impairment, jaundice, cholestatic jaundice, cirrhosis, liver necrosis, liver failure, Kawasaki-like syndrome (including changes in liver enzymes), transient elevations in liver function tests, hypersensitivity hepatitis, hepatic failure
Postmarketing reports: Elevated AST (SGOT) or ALT (SGPT), elevated gamma-glutamyltransferase, elevated bilirubin, hepatitis, jaundice, cholecystitis, cholestatic jaundice, liver necrosis, liver failure, Kawasaki-like syndrome (including changes in liver enzymes)[Ref]

A 42-year-old male with ulcerative colitis was admitted for investigation of prolonged fever associated with cholestatic liver tests. Endoscopic retrograde cholangiopancreatography demonstrated a normal biliary tree, and liver biopsy showed granulomata. The symptoms disappeared after cessation of mesalamine therapy and recurred on rechallenge.

Hypersensitivity hepatitis associated with mesalamine appears to occur less commonly than with sulfasalazine.

Hepatic failure has been reported in patients with preexisting liver disease.[Ref]


Renal impairment (including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure) has been reported with products that contain mesalamine (the active ingredient contained in Canasa Pac) or are converted to mesalamine.

Renal tubular dysfunction has been reported, although a definitive causality has not been established.[Ref]

Common (1% to 10%): Decreased creatinine clearance (less than 3%)
Frequency not reported: Nephrogenic diabetes insipidus, nephrotic syndrome, renal impairment, renal tubular dysfunction
Postmarketing reports: Renal failure, interstitial nephritis, minimal change nephropathy, elevated blood urea nitrogen, elevated serum creatinine[Ref]


Common (1% to 10%): Dysmenorrhea (3%), hematuria (less than 3%), urinary frequency (2% or greater)
Rare (less than 0.1%): Oligospermia, infertility in men
Frequency not reported: Albuminuria, amenorrhea, breast pain, hypomenorrhea, metrorrhagia, urinary burning
Postmarketing reports: Dysuria, urinary urgency, hematuria, epididymitis, menorrhagia, reversible oligospermia[Ref]

Rarely, oligospermia and infertility in men have been reported and have been attributed to sulfasalazine.[Ref]


Common (1% to 10%): Anxiety (2% or greater), nervousness (2% or greater)
Frequency not reported: Lethargy, mild disorientation, decreased libido
Postmarketing reports: Depression, emotional lability, confusion[Ref]


Common (1% to 10%): Elevated triglycerides (less than 3%)
Postmarketing reports: Anorexia, increased appetite, elevated alkaline phosphatase, elevated lactate dehydrogenase[Ref]


Common (1% to 10%): Vision abnormalities (2% or greater), conjunctivitis (up to 2%)
Postmarketing reports: Eye pain, blurred vision[Ref]


Rectal suspension enemas:
Common (1% to 10%): Pain on insertion of enema tip (1.35%), hemorrhoids (1.35%), rectal pain (1.23%)
Uncommon (0.1% to 1%): Rectal pain/soreness/burning (0.61%)
Frequency not reported: Perianal irritation[Ref]


1. "Encapsulated mesalamine granules (apriso) for ulcerative colitis." Obstet Gynecol 114 (2009): 686-7

2. Fiorentini MT, Fracchia M, Galatola G, Barlotta A, de la Pierre M "Acute pancreatitis during oral 5-aminosalicylic acid therapy." Dig Dis Sci 35 (1990): 1180-2

3. Sachedina B, Saibil F, Cohen LB, Whittey J "Acute pancreatitis due to 5-aminosalicylate." Ann Intern Med 110 (1989): 490-2

4. Isaacs KL, Murphy D "Pancreatitis after rectal administration of 5-aminosalicylic acid." J Clin Gastroenterol 12 (1990): 198-9

5. Deprez P, Descamps C, Fiasse R "Pancreatitis induced by 5-aminosalicylic acid." Lancet 2 (1989): 445-6

6. Green JRB, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJF, Parkins KJ, Taylor MD "Basalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis (Vol 114, pg 15, 1998)." Gastroenterology 114 (1998): 864-5

7. "Product Information. Pentasa Product Information (mesalamine)." Hoechst Marion-Roussel Inc, Kansas City, MO.

8. "Product Information. Apriso (mesalamine (5-aminosalicylic acid))." Salix Pharmaceuticals, Raleigh, NC.

9. "Product Information. Asacol product information (mesalamine)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.

10. Tran K, Froguel E, Jian R, Lemann M, Modigliani R "Acute pancreatitis induced by mesalazine." J Clin Gastroenterol 13 (1991): 715-6

11. Brimblecombe R "Mesalazine: a global safety evaluation." Scand J Gastroenterol Suppl 172 (1990): 66-8

12. Habal FM, Greenberg GR "Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine." Am J Gastroenterol 83 (1988): 15-9

13. Prakash A, Markham A "Oral delayed-release mesalazine - A review of its use in ulcerative colitis and Crohn's disease." Drugs 57 (1999): 383-408

14. "Product Information. Rowasa product information (mesalamine)." Solvay Pharmaceuticals Inc, Marietta, GA.

15. Danish 5-ASA Group "Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis: a randomized, double-blind multicenter trial." Dig Dis Sci 32 (1987): 598-602

16. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH "Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands." Am J Gastroenterol 94 (1999): 2417-22

17. Loftus EV, Kane SV, Bjorkman D "Safety of 5-aminosalicylic acid agents in the treatment of ulcerative colitis: a systematic review." Am J Gastroenterol 98(9S) (2003): S249

18. "Product Information. Lialda (mesalamine (5-aminosalicylic acid))." Shire US Inc, Florence, KY.

19. "Product Information. Delzicol (mesalamine (5-aminosalicylic acid))." Warner Chilcott Laboratories, Rockaway, NJ.

20. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA "Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse." Gut 29 (1988): 669-74

21. "Product Information. Canasa (mesalamine (5-aminosalicylic acid))." Axcan Scandipharm Inc, Birmingham, AL.

22. Fine KD, Sarles HE, Cryer B "Diarrhea associated with mesalamine in a patient with chronic nongranulomatous enterocolitis." N Engl J Med 338 (1998): 923-5

23. "Encapsulated mesalamine granules (apriso) for ulcerative colitis." Med Lett Drugs Ther 51 (2009): 38-9

24. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL "Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group." Gastroenterology 104 (1993): 1293-301

25. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M "Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group." Am J Gastroenterol 88 (1993): 1188-97

26. Woodward DK "Peripheral neuropathy and mesalazine." BMJ 299 (1989): 1224

27. Rosa N, Giamundo A, Jura A, Iaccarino G, Romano A "Mesalazine-associated benign intracranial hypertension in a patient with ulcerative colitis." Am J Ophthalmol 136 (2003): 212-3

28. Lim AG, Hine KR "Fever, vasculitic rash, arthritis, pericarditis, and pericardial effusion after mesalazine." BMJ 308 (1994): 113

29. le Gros V, Saveuse H, Lesur G, Brion N "Lung and skin hypersensitivity to 5-aminosalicylic acid." BMJ 302 (1991): 970

30. Sesin GP, Mucciardi N, Almeida S "Mesalamine-associated pleural effusion with pulmonary infiltration." Am J Health Syst Pharm 55 (1998): 2304-5

31. Welte T, Hamm H, Fabel H "Mesalazine alveolitis [published erratum appears in Lancet 1992 Jan 4;339(8784):70]." Lancet 338 (1991): 1273

32. Muzzi A, Ciani F, Bianchini D, Volpe C "Adverse pulmonary effects of mesalamine." Chest 108 (1995): 1181

33. Honeybourne D "Mesalazine toxicity." BMJ 308 (1994): 533-4

34. Reinoso MA, Schroeder KW, Pisani RJ "Lung disease associated with orally administered mesalamine for ulcerative colitis." Chest 101 (1992): 1469-71

35. Agnholt J, Sorensen HT, Rasmussen SN, Gotzsche CO, Halkier P "Cardiac hypersensitivity to 5-aminosalicylic acid." Lancet 1 (1989): 1135

36. Jenss H, Becker EW, Weber P "Pericardial effusion during treatment with 5-aminosalicylic acid in a patient with Crohn's disease." Am J Gastroenterol 85 (1990): 332-3

37. Gujral N, Friedenberg F, Friedenberg J, Gabriel G, Kotler M, Levine G "Pleuropericarditis related to the use of mesalamine." Dig Dis Sci 41 (1996): 624-6

38. Asirvatham S, Sebastian C, Thadani U "Severe symptomatic sinus bradycardia associated with mesalamine use." Am J Gastroenterol 93 (1998): 470-1

39. Pent MT, Ganapathy S, Holdsworth CD, Channer KC "Mesalazine induced lupus-like syndrome." BMJ 305 (1992): 159

40. Asirvatham S, Sebastian C, Thadani U "Re: Severe symptomatic sinus bradycardia associated with mesalamine use. (Vol 93, pg 470, 1998)." Am J Gastroenterol 93 (1998): 1196

41. Kristensen KS, Hoegholm A, Bohr L, Friis S "Fatal myocarditis associated with mesalazine." Lancet 335 (1990): 605

42. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S, Briggs RL, Lawlis V, Felger C, Kitzmiller G, Liebermann T, Frachtman R, Fi "Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis." Dig Dis Sci 40 (1995): 296-304

43. Alstead EM, Wilson AG, Farthing MJ "Lichen planus and mesalazine." J Clin Gastroenterol 13 (1991): 335-7

44. Kutty PK, Raman KR, Hawken K, Barrowman JA "Hair loss and 5-aminosalicylic acid enemas." Ann Intern Med 97 (1982): 785-6

45. Lizasoain J, Rubio FA, Erdozain JC, Olveira A, Conde P "Folliculitis and mesalamine." Am J Gastroenterol 91 (1996): 819-20

46. Daneshmend TK "Mesalazine-associated thrombocytopenia." Lancet 337 (1991): 1297-8

47. Abboudi ZH, Marsh JC, Smith-Laing G, Gordon-Smith EC "Fatal aplastic anaemia after mesalazine." Lancet 343 (1994): 542

48. Farrell RJ, Peppercorn MA, Michetti P "Mesalamine-associated thrombocytopenia." Am J Gastroenterol 94 (1999): 2304-6

49. Stelts S, Taylor MH, Nappi J, Van Bakel AB "Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis." Ann Pharmacother 42 (2008): 904-5

50. Niv Y "Hypersensitivity to 5-aminosalicylic acid in patients with ulcerative colitis." Isr J Med Sci 23 (1987): 1161-3

51. Waanders H, Thompson J "Kawasaki-like syndrome after treatment with mesalazine." Am J Gastroenterol 86 (1991): 219-21

52. Aparicio J, Carnicer F, Girona E, Gomez A "Cutaneous hypersensitivity reaction to mesalazine." Am J Gastroenterol 91 (1996): 620-1

53. Sentongo TAS, Piccoli DA "Recurrent pericarditis due to mesalamine hypersensitivity: A pediatric case report and review of the literature." J Pediatr Gastroenterol Nutr 27 (1998): 344-7

54. Kounis GN, Kouni SA, Chiladakis JA, Kounis NG "Comment: Mesalamine-Associated Hypersensitivity Myocarditis in Ulcerative Colitis and the Kounis Syndrome (February)." Ann Pharmacother 43 (2009): 393-4

55. Brogden RN, Sorkin EM "Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease." Drugs 38 (1989): 500-23

56. Hautekeete ML, Bourgeois N, Potvin P, Duville L, Reynaert H, Devis G, Adler M, Kloppel G "Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine." Gastroenterology 103 (1992): 1925-7

57. Braun M, Fraser GM, Kunin M, Salamon F, Kaspa RT "Mesalamine-induced granulomatous hepatitis." Am J Gastroenterol 94 (1999): 1973-4

58. Masson EA, Rhodes JM "Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss." Gut 33 (1992): 563-4

59. Elseviers MM, D'Haens G, Lerebours E, et al. "Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?" Clin Nephrol 61 (2004): 83-9

60. Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442

61. Van Staa TP, Travis S, Leufkens HG, Logan RF "5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic study." Gastroenterology 126 (2004): 1733-9

62. Thuluvath PJ, Ninkovic M, Calam J, Anderson M "Mesalazine induced interstitial nephritis." Gut 35 (1994): 1493-6

63. Schreiber S. Hamling J, Zehnter E, et al "Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate." Gut 40 (1997): 761-6

64. Mehta RP "Acute interstitial nephritis due to 5-aminosalicylic acid." Can Med Assoc J 143 (1990): 1031-2

65. Izzedine H, Simon J, Piette AM, et al. "Primary chronic interstitial nephritis in Crohn's disease." Gastroenterology 123 (2002): 1436-1440

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.